P31Q Stock Overview
An investment firm primarily focused on investing in public and private debt securities. More details
Snowflake Score | |
---|---|
Valuation | 4/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 3/6 |
Dividends | 2/6 |
Mount Logan Capital Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$1.28 |
52 Week High | US$1.42 |
52 Week Low | US$0.94 |
Beta | -0.071 |
11 Month Change | -0.78% |
3 Month Change | -2.29% |
1 Year Change | 4.06% |
33 Year Change | -53.96% |
5 Year Change | n/a |
Change since IPO | -29.28% |
Recent News & Updates
Recent updates
Shareholder Returns
P31Q | DE Diversified Financial | DE Market | |
---|---|---|---|
7D | 1.6% | -0.7% | 0.2% |
1Y | 4.1% | 4.8% | 8.5% |
Return vs Industry: P31Q matched the German Diversified Financial industry which returned 4.8% over the past year.
Return vs Market: P31Q underperformed the German Market which returned 8.5% over the past year.
Price Volatility
P31Q volatility | |
---|---|
P31Q Average Weekly Movement | 4.5% |
Diversified Financial Industry Average Movement | 3.6% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.9% |
10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: P31Q has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: P31Q's weekly volatility (4%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
n/a | 21 | Ted Goldthorpe | www.mountlogancapital.ca |
Mount Logan Capital Inc.is an investment firm primarily focused on investing in public and private debt securities. The Company holds and actively manages and monitors a seed portfolio of loans and other investments with credit-oriented characteristics. The company was formerly known as Marret Resource Corp. and changed its name to Mount Logan Capital Inc. in October 2018.
Mount Logan Capital Inc. Fundamentals Summary
P31Q fundamental statistics | |
---|---|
Market cap | €36.91m |
Earnings (TTM) | -€3.10m |
Revenue (TTM) | €137.39m |
0.3x
P/S Ratio-11.9x
P/E RatioIs P31Q overvalued?
See Fair Value and valuation analysisEarnings & Revenue
P31Q income statement (TTM) | |
---|---|
Revenue | US$143.07m |
Cost of Revenue | US$105.90m |
Gross Profit | US$37.17m |
Other Expenses | US$40.40m |
Earnings | -US$3.23m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -0.13 |
Gross Margin | 25.98% |
Net Profit Margin | -2.26% |
Debt/Equity Ratio | 156.7% |
How did P31Q perform over the long term?
See historical performance and comparison